Fervent Synerg.

Why is Fervent Synergies Ltd falling/rising?

As of 12-Jul, Fervent Synergies Ltd's stock price is rising to 15.38, reflecting a 4.27% increase after a trend reversal. Increased investor participation and outperformance against its sector suggest a potential short-term bullish trend.

As of 12-Jul, Fervent Synergies Ltd's stock price is rising, currently at 15.38, reflecting an increase of 0.63 or 4.27%. This upward movement follows a trend reversal after four consecutive days of decline, indicating a potential shift in investor sentiment. Additionally, the stock has outperformed its sector by 4.04% today, suggesting stronger performance relative to its peers.<BR><BR>Investor participation has also increased, with a notable rise in delivery volume by 125.99% compared to the 5-day average, which may indicate growing interest among investors. Furthermore, the stock's current price is above both the 5-day and 20-day moving averages, although it remains below the longer-term moving averages (50-day, 100-day, and 200-day). This positioning could suggest a short-term bullish trend while still being cautious in the longer term.<BR><BR>Overall, the combination of a trend reversal, increased investor participation, and outperformance against the sector contributes to the current rise in Fervent Synergies Ltd's stock price.

Which are the latest news on Fervent Synerg.?

How big is Fervent Synerg.?

As of 10th June, Fervent Synergies Ltd has a market capitalization of 76.00 Cr, with recent net sales of 16.34 Cr and a net profit of 3.82 Cr. Shareholder's funds are 48.64 Cr, and total assets amount to 48.78 Cr.

As of 10th June, Fervent Synergies Ltd has a market capitalization of 76.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Fervent Synergies Ltd reported Net Sales of 16.34 Cr and a Net Profit of 3.82 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 48.64 Cr and Total Assets of 48.78 Cr.

Who are in the management team of Fervent Synerg.?

The management team of Fervent Synerg includes Vijay P Thakkar (Chairman, CEO), Karan V Thakkar (CFO), Sanjay P Thakkar (Managing Director), and independent directors Nitin B Parikh, Rajesh M Maheshwari, and Falguni Kaushik Mehta. They oversee the company's strategic direction and operations.

The management team of Fervent Synerg includes the following individuals:<BR><BR>1. **Vijay P Thakkar** - Chairman, Executive Director, and CEO<BR>2. **Karan V Thakkar** - Executive Director and Chief Financial Officer<BR>3. **Sanjay P Thakkar** - Executive Director, Managing Director, and Promoter<BR>4. **Nitin B Parikh** - Independent Non-Executive Director<BR>5. **Rajesh M Maheshwari** - Independent Non-Executive Director<BR>6. **Falguni Kaushik Mehta** - Independent Non-Executive Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Who are the peers of the Fervent Synerg.?

Fervent Synerg.'s peers include Lykis, Cravatex, Sunrise Efficie., Ashnisha Indus., Variman Global, Uma Exports, Bombay Cycle, Ganesha Ecoverse, and Eforu Entertainm. Fervent Synerg. has a Below Average management risk and a 1-year return of -23.08%, better than Cravatex but worse than Lykis, which has the highest return at 35.87%.

Peers: The peers of Fervent Synerg. are Lykis, Cravatex, Sunrise Efficie., Ashnisha Indus., Variman Global, Uma Exports, Bombay Cycle, Ganesha Ecoverse, and Eforu Entertainm.<BR><BR>Quality Snapshot: Below Average management risk is observed at Lykis, Ashnisha Indus., Variman Global, Uma Exports, Bombay Cycle, Ganesha Ecoverse, Eforu Entertainm, and Fervent Synerg., while Average management risk is found at Cravatex and Sunrise Efficie. Excellent growth is noted at Sunrise Efficie., with Good growth at Lykis and Fervent Synerg., while the rest exhibit Below Average growth. Excellent capital structure is seen at Sunrise Efficie. and Variman Global, while Below Average capital structure is present at Lykis, Cravatex, Fervent Synerg., Ashnisha Indus., Uma Exports, Bombay Cycle, Ganesha Ecoverse, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Lykis at 35.87%, while Cravatex has the lowest at -22.72%. Fervent Synerg.'s 1-year return is -23.08%, which is lower than Lykis but higher than Cravatex. Additionally, several peers, including Sunrise Efficie., Uma Exports, Variman Global, and Ganesha Ecoverse, have negative six-month returns.

What does Fervent Synerg. do?

Fervent Synergies Ltd, a Micro Cap company in the Trading & Distributors industry, reported net sales of 5 Cr and a net profit of 1 Cr for the quarter ending March 2026. The company, incorporated in 2009, has a market cap of INR 76 Cr and key metrics include a P/E of 20.00 and a debt-equity ratio of 0.01.

Overview: <BR>Fervent Synergies Ltd operates in the Trading & Distributors industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Fervent Synergies Ltd was incorporated in 2009 as Fervent Pharma Synergies Limited and changed its name to Fervent Synergies Limited on July 24, 2012. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 5 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 76 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 20.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.01 <BR>Return on Equity: 6.68% <BR>Price to Book: 1.40 <BR><BR>Contact Details: <BR>Address: B-7/8 Satyam Commercial Comple, M G Road Ghatkopar (East) Mumbai Maharashtra : 400077 <BR>Tel: 91-22-25017801/02/03 <BR>Email: info@ferventsynergies.com <BR>Website: http://www.ferventsynergies.com

Should I buy, sell or hold Fervent Synergies Ltd?

Are Fervent Synergies Ltd latest results good or bad?

Fervent Synergies Ltd's latest results are concerning, showing a significant increase in net profit and operating margin, but stagnant and volatile revenue, leading to a "Strong Sell" rating. The stock has declined 16.03% over the past year, indicating substantial operational challenges.

Fervent Synergies Ltd's latest results indicate a troubling situation overall. While there are some positive signs, such as a significant year-on-year increase in net profit and operating margin, the company's revenue remains alarmingly low and has shown extreme volatility. <BR><BR>In the most recent quarter, net profit was ₹0.43 crores, reflecting a substantial 975% increase year-on-year, and the operating margin improved to 64.71%. However, net sales were stagnant at ₹0.68 crores, which is a drastic decline from ₹26.33 crores reported in December 2024. This inconsistency raises concerns about the sustainability of the company's business model.<BR><BR>The stock has struggled significantly, declining 16.03% over the past year while the Sensex gained 6.49%. Currently, the stock trades at ₹19.49, which is 34.60% below its 52-week high. The company has a low Mojo score of 23 out of 100, indicating a "Strong Sell" rating due to deteriorating fundamentals and unfavorable technical positioning.<BR><BR>Overall, while there are some improvements in profitability metrics, the erratic revenue patterns and lack of scale suggest significant operational challenges. Therefore, the latest results can be characterized as concerning, with multiple red flags indicating a high-risk investment.

When is the next results date for Fervent Synergies Ltd?

The next results date for Fervent Synergies Ltd is February 5, 2026.

The next results date for Fervent Synergies Ltd is scheduled for February 5, 2026.

Is Fervent Synerg. overvalued or undervalued?

As of December 2, 2025, Fervent Synerg. is fairly valued with a PE ratio of 25.56 and a PEG ratio of 0.22, making it more attractive compared to peers like Sun Pharma and Divi's Lab, despite recent underperformance against the Sensex.

As of 2 December 2025, Fervent Synerg. has moved from an expensive to a fair valuation grade. The company is currently fairly valued based on its financial metrics, with a PE ratio of 25.56, an EV to EBITDA ratio of 25.36, and a PEG ratio of 0.22. These ratios indicate a more reasonable valuation compared to its peers.<BR><BR>In comparison to its industry peers, Fervent Synerg. stands out with a lower PE ratio than Sun Pharma. Industries, which has a PE of 37.36, and Divi's Lab., which is at 68.62. Additionally, Fervent's PEG ratio of 0.22 is significantly more attractive than that of its competitors, suggesting potential for growth relative to its price. Despite recent underperformance against the Sensex, with a 1-week return of -16.21% compared to the Sensex's 0.65%, the current valuation appears justified given the overall market context.

How has been the historical performance of Fervent Synerg.?

Fervent Synerg. has shown significant revenue growth, with net sales increasing from 0.68 Cr in Mar'22 to 32.46 Cr in Mar'25, and a return to profitability with a profit after tax of 2.95 Cr in Mar'25. However, the company still faces negative cash flow from operating activities at -15.00 Cr in Mar'25.

Answer:<BR>The historical performance of Fervent Synerg. shows significant fluctuations in its financial metrics over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Fervent Synerg. has experienced a notable increase in net sales, rising from 0.68 Cr in Mar'22 to 32.46 Cr in Mar'25, reflecting a strong growth trajectory. Total operating income followed a similar trend, reaching 32.46 Cr in Mar'25 compared to just 0.68 Cr in Mar'22. However, total expenditure peaked at 37.07 Cr in Mar'24 before decreasing to 29.47 Cr in Mar'25, which contributed to an operating profit of 2.99 Cr in Mar'25, a significant recovery from the loss of 12.76 Cr in the previous year. Profit before tax also improved to 2.95 Cr in Mar'25 from a loss of 12.85 Cr in Mar'24, leading to a profit after tax of 2.95 Cr in Mar'25, compared to a loss of 12.84 Cr in Mar'24. The company's equity capital increased to 43.75 Cr in Mar'25 from 30.00 Cr in Mar'24, and total assets rose to 48.78 Cr in Mar'25 from 30.51 Cr in Mar'24. Despite these improvements, the cash flow from operating activities remained negative at -15.00 Cr in Mar'25, indicating challenges in cash generation despite profitability. Overall, while Fervent Synerg. has shown strong revenue growth and a return to profitability, it faces ongoing cash flow issues.

What is the technical trend for Fervent Synerg.?

As of May 22, 2025, Fervent Synerg's technical trend is mildly bullish, supported by daily moving averages and a bullish monthly MACD, despite mixed signals from the weekly MACD and Bollinger Bands.

As of 22 May 2025, the technical trend for Fervent Synerg has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD remains bullish, indicating mixed signals. The daily moving averages suggest a mildly bullish stance, contrasting with the weekly Bollinger Bands, which are mildly bearish. The KST shows a bearish trend on the weekly chart but bullish on the monthly. Overall, the lack of clear trends in Dow Theory and the neutral signals from the RSI suggest a cautious outlook. The current technical stance is mildly bullish, driven primarily by the daily moving averages and the monthly MACD.

Who are the top shareholders of the Fervent Synerg.?

The top shareholder of Fervent Synerg is Vijay Thakkar, with a 57.49% stake. Other notable shareholders include Blue Berry Securities Pvt Ltd at 5.66% and individual investors with a combined 8.44%.

The top shareholders of Fervent Synerg include Vijay Thakkar, who holds the largest stake at 57.49%. The company is primarily owned by its promoters, with no pledged promoter holdings reported. The highest public shareholder is Blue Berry Securities Pvt Ltd, which holds 5.66%. Additionally, individual investors collectively own 8.44% of the company. There is also one Foreign Institutional Investor (FII) involved, but they hold a negligible percentage of 0.0%.

Has Fervent Synerg. declared dividend?

No Dividend History Available